Loading…
Tempest Therapeutics, Inc. is projected to decline to $0.839 by 2027, a -4% move from its current price of $0.8751. TPST is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.8466 | $0.8749 | $0.9042 | -0.02% |
| Aug 6 | $0.835 | $0.8748 | $0.9164 | -0.04% |
| Aug 7 | $0.8261 | $0.8746 | $0.9259 | -0.06% |
| Aug 8 | $0.8187 | $0.8744 | $0.9339 | -0.08% |
| Aug 9 | $0.8122 | $0.8743 | $0.941 | -0.10% |
| Aug 10 | $0.8064 | $0.8741 | $0.9475 | -0.12% |
| Aug 11 | $0.801 | $0.8739 | $0.9534 | -0.13% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.801 | $0.8739 | $0.9534 | -0.13% |
| Week 2 | $0.7716 | $0.8727 | $0.9871 | -0.27% |
| Week 3 | $0.7495 | $0.8716 | $1.01 | -0.40% |
| Week 4 | $0.7313 | $0.8704 | $1.04 | -0.54% |
| Week 5 | $0.7154 | $0.8692 | $1.06 | -0.67% |
| Week 6 | $0.7013 | $0.8681 | $1.07 | -0.81% |
| Week 7 | $0.6885 | $0.8669 | $1.09 | -0.94% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F.
Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate.
Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Tempest Therapeutics, Inc. (TPST) is a healthcare company focused on cancer therapeutics. The stock currently trades at $0.871 with a market cap of $13.92M and a rank of 4768. These figures place TPST among small-cap biotechnology listings.
The forecast data show a flat start in 2026 with the average price at $0.871 and a max of $1.09, implying a neutral near-term outlook.
A major floor 32.6% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.2% away) — a key level to hold.
The nearest ceiling, 43.4% above — a clean break opens room to run.
A major ceiling 157.1% above — clearing it would confirm fresh momentum.
Key TPST support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TPST market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.8836 | Sell | $0.8821 | Sell |
| MA 10 | $0.9178 | Sell | $0.9119 | Sell |
| MA 20 | $0.9576 | Sell | $0.9717 | Sell |
| MA 50 | $1.19 | Sell | $1.20 | Sell |
| MA 100 | $1.56 | Sell | $1.73 | Sell |
| MA 200 | $3.14 | Sell | $3.31 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 28.85 | Buy |
| Stoch RSI (14) | 31.34 | Neutral |
| CCI (20) | -157.46 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -20.00 | Sell |
| Bollinger %B (20,2) | 0.05 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -1.21 | Sell |
| Awesome (5,34) | -0.16 | Sell |
| Ultimate (7,14,28) | 25.08 | Buy |
| Momentum (10) | -0.11 | Sell |
| Aroon Osc (25) | -84.00 | Sell |
| Hull MA (9) | 0.85 | Buy |
| ADX (14) | 39.44 | Sell |
| ATR (14) | 0.03 | Info |
In the near term, the sentiment is NEUTRAL and near-term indicators are subdued. The RSI(14) sits at 30, with the 50-day simple moving average at $1.27 and the 200-day simple moving average at $3.34, suggesting limited upside pressure relative to longer-term averages. Support is noted at $0.926 and resistance at $1.26, framing a tight near-term range.
The 30-day price range spans from $0.6982 to $1.09, and annualized volatility stands at 60%, indicating notable volatility despite a neutral directional tilt.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.856 | $0.8751 | $1.10 | 0% | Neutral | |
| $0.6568 | $0.839 | $1.14 | -4% | Neutral | |
| $0.6204 | $0.8207 | $1.17 | -6% | Neutral | |
| $0.6023 | $0.8201 | $1.21 | -6% | Neutral | |
| $0.515 | $0.7194 | $1.09 | -18% | Bearish | |
| $0.6113 | $0.8741 | $1.36 | 0% | Neutral | |
| $0.7337 | $1.07 | $1.70 | +23% | Bullish | |
| $0.6647 | $0.9919 | $1.60 | +13% | Neutral | |
| $0.6712 | $1.02 | $1.68 | +17% | Neutral | |
| $0.6447 | $0.9997 | $1.67 | +14% | Neutral | |
| $0.8466 | $1.43 | $2.57 | +64% | Bullish | |
| $1.22 | $2.40 | $4.78 | +175% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.856 | $0.8751 | $1.08 | +0.00% |
| September 2026 | $0.7368 | $0.8763 | $1.07 | +0.13% |
| October 2026 | $0.717 | $0.8599 | $1.07 | -1.87% |
| November 2026 | $0.7266 | $0.8774 | $1.10 | +2.04% |
| December 2026 | $0.7152 | $0.869 | $1.10 | -0.96% |
Click any year to see its month-by-month TPST forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, TPST could reach as high as $1.10, with a base case around $0.8751 and support toward $0.856 — roughly 0% from $0.8751. Price action looks broadly range-bound.
Expect TPST to range from $0.6568 to $1.14 through 2027. The $0.839 average target implies a -4% move from current prices. That is -4% versus the projected 2026 average. A consolidation phase looks the most probable path here.
The TPST price prediction for 2028 points to an average of $0.8207 (low $0.6204, high $1.17) — a potential decline of -6% on today's $0.8751. Price action looks broadly range-bound.
In 2029, TPST is projected to trade between $0.6023 and $1.21, averaging $0.8201 — a potential decline of -6% from today's $0.8751. That is 0% versus the projected 2028 average. A consolidation phase looks the most probable path here.
Tempest Therapeutics, Inc.'s 2030 outlook centres on $0.7194, within a $0.515 to $1.09 range. That is -12% versus the projected 2029 average. That marks a -18% change versus current levels. A cyclical pullback looks likely — prices rarely move in a straight line.
By 2031, TPST could reach as high as $1.36, with a base case around $0.8741 and support toward $0.6113 — roughly 0% from $0.8751. A consolidation phase looks the most probable path here.
Expect TPST to range from $0.7337 to $1.70 through 2032. The $1.07 average target implies a +23% move from current prices. That is up +23% on the projected 2031 average. Momentum favours further upside here.
The TPST price prediction for 2033 points to an average of $0.9919 (low $0.6647, high $1.60) — a potential gain of +13% on today's $0.8751. A consolidation phase looks the most probable path here.
In 2034, TPST is projected to trade between $0.6712 and $1.68, averaging $1.02 — a potential gain of +17% from today's $0.8751. That is up +3% on the projected 2033 average. Price action looks broadly range-bound.
Tempest Therapeutics, Inc.'s 2035 outlook centres on $0.9997, within a $0.6447 to $1.67 range. That is -2% versus the projected 2034 average. That marks a +14% change versus current levels. A consolidation phase looks the most probable path here.
By 2040, TPST could reach as high as $2.57, with a base case around $1.43 and support toward $0.8466 — roughly +64% from $0.8751. Momentum favours further upside here.
Expect TPST to range from $1.22 to $4.78 through 2050. The $2.40 average target implies a +175% move from current prices. That is up +68% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in TPST today (≈ 1,142.726546 TPST) could be worth
$2,745.47
+$1,745.47 (+175%) by 2050 · US Dollar
Based on the average projected TPST price of $2.4 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TPSTwould be worth at today's price.
$1,000 invested in TPST on Jul 31, 2025 (≈ 138.312586 TPST) would be worth
$121.04
-$878.96 (-87.9%) today · 0.12× · US Dollar
Based on a TPST entry price of $7.23 vs. today's $0.8751.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.926 | $945.03 | -5.5% |
| 1 month ago | $1.11 | $788.38 | -21.2% |
| 3 months ago | $2.04 | $428.97 | -57.1% |
| 6 months ago | $2.47 | $354.29 | -64.6% |
| 1 year ago | $7.23 | $121.04 | -87.9% |
| All time (5.0y) ago | $164.32 | $5.33 | -99.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TPST forecast.
Our base-case forecast reaches $1.80 around 2050.
Implied market cap at $1.80: $28.76M
The multi-year forecast shows a mixed path with periods of stability and growth. In 2030 the stock is forecasted to be Bearish with an average price of $0.7142 and a max of $1.09, yielding a -18% ROI. The sentiment for 2030 is Bearish, highlighting a valuation trough before potential recovery in later years.
By 2040, the outlook turns Bullish, with an average price of $1.43 and a max of $2.59, delivering a 64.5% ROI. The 2050 forecast remains Bullish, with an average price of $2.37 and a max of $4.76, corresponding to a 172.6% ROI. The forecast also shows higher upside potential in the later years, including a 2032 year with an average of $1.06 and a 22.1% ROI, and a 2031 year with an average of $0.8773 and a 0.7% ROI, underscoring a broad recovery from the 2030 dip.
These are estimates and not guarantees of future performance, and actual results may vary with market conditions and company developments.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $0.7142 with a max of $1.09 and a -18% ROI, i.e., a Bearish sentiment for that year.
The forecast indicates a mix of Neutral periods and Bullish turns, with 2030 showing Bearish (avg $0.7142, ROI -18) and 2040/2050 showing Bullish upside (avg $1.43, ROI 64.5 in 2040; avg $2.37, ROI 172.6 in 2050). These are estimates, not guarantees.
Yes. The 2050 forecast lists a max price of $4.76, well above $3.00, with an average of $2.37 and a 172.6% ROI for that year.
Current price is $0.871 and market cap is $13.92M.
Sentiment is NEUTRAL with RSI(14) at 30. The SMA50 is $1.27 and the SMA200 is $3.34. Support is $0.926 and resistance is $1.26. The 30-day range is $0.6982 to $1.09, and annualized volatility is 60%.
Tempest Therapeutics, Inc. Community Discussion
0Share your Tempest Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.